Analysts See $-0.06 EPS for CytoDyn Inc. (CYDY)

June 19, 2018 - By Ellis Scott

CytoDyn Inc. (OTCMKTS:CYDY) Logo

Analysts expect CytoDyn Inc. (OTCMKTS:CYDY) to report $-0.06 EPS on July, 19. The stock decreased 3.08% or $0.0148 during the last trading session, reaching $0.4652. About 101,624 shares traded. CytoDyn Inc. (OTCMKTS:CYDY) has 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. The company has market cap of $101.74 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. It currently has negative earnings.

CytoDyn Inc. (OTCMKTS:CYDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: